References I-54

1. Aldurazyme® (laronidase) [package insert]. BioMarin Pharmaceutical, Inc.; Novarto, CA, Revised 12/2019.

2. Harada H, Niiyama H, Katoh A, et al. Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis I. JIMD Reports. 2014; 16:39–45.

3. Beck M, Arn P, Giugliani R, et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet in Med. 2014; 16(10):759–765.

4. Ou L, Herzog T, Koniar B, et al. High-dose enzyme replacement therapy in Murine Hurler Syndrome. Mol genet metab. 2014; 111(2):116-122.

5. Sannaa N, Bay L, Barbouth D, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: A retrospective case series analysis of nine sibships. Orphanet J of Rare Dis. 2015; 10:131.

6. Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, et al. Agreement between the results of metaanalyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases. Mol Gene Metab. 2018; 1-7.

7. Xue Y, Richards SM, Mahmood A, Cox GF. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies. Mol Gene Metab. 2016; 419–426.

8. MICROMEDEX®SOLUTIONS Compendia. 2020. Laronidase.

9. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Laronidase.

10. Dornelles A, Artigalas O, Anjos da Silva A, et al. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis. PLoS ONE. 2017; 12(8): 1-18.

11. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.

12. MCG[™] Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).

13. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. Healthcare. 2016.

14. Laronidase In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2020.

15. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.

16. Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. *Cochrane Database of Systematic Reviews*. 2019;6:1-24.